

Partner, Boston

Tax



T: 617.573.4837  
moshe.spinowitz@skadden.com

## Education

J.D., Harvard Law School, 2006  
(*magna cum laude*; Articles Editor,  
*Harvard Law Review*)

B.A., Harvard College, 2002  
(*summa cum laude*)

## Bar Admissions

Massachusetts  
District of Columbia

## Experience

Law Clerk to Judge Michael Boudin,  
U.S. Court of Appeals for the  
First Circuit

Law Clerk to Associate Justice  
Antonin Scalia, U.S. Supreme Court

Moshe Spinowitz advises multinational companies in connection with cross-border mergers and acquisitions, and post-acquisition restructuring and integration transactions. He also represents clients on a range of tax controversy matters during all phases of IRS audits and appeals.

Mr. Spinowitz has advised several multinational companies on the integration and restructuring of their operations following large cross-border acquisitions. He also has counseled pharmaceutical and technology companies in connection with the structuring of their intellectual property holdings, as well as a variety of companies in connection with U.S. tax reform. Mr. Spinowitz also has successfully represented several multinational corporations before IRS appeals involving intercompany financing transactions and other cross-border tax matters.

Select representations include:

- **Bottomline Technologies** in its pending \$2.6 billion acquisition by Thomas Bravo;
- **Dicerna Pharmaceuticals** in its \$3.3 billion acquisition by Novo Nordisk;
- **Waldencast Acquisition Corp.** in its pending business combination with Obagi Cosmeceuticals and Milk Makeup;
- **L'Occitane International** in its acquisition of Sol de Janeiro Holdings;
- **AspenTech** in its pending \$11 billion combination with the industrial software business of Emerson Electric;
- **ArQule, Inc.** in its \$2.7 billion acquisition by a subsidiary of Merck & Co., Inc.;
- **Juno Therapeutics** in its \$9 billion acquisition by Celgene;
- **Clementia Pharmaceuticals Inc.** in its \$1.3 billion acquisition by Ipsen S.A.;
- **Gilead Sciences, Inc.** in its \$11.9 billion acquisition of Kite Pharma, its acquisition of Cell Design Labs for up to \$567 million, and its research and development collaboration with, and equity investment in, Galapagos NV;
- **Biogen Inc.** in the spin-off of its hemophilia business as an independent public company called Bioverativ;
- **Konecranes plc** in its acquisition of Terex Corporation's material handling and port solutions unit for \$1.28 billion;
- **Merrimack Pharmaceuticals, Inc.** in its sale of cancer treatment drugs Onivyde and generic Doxil to Ipsen S.A. for up to \$1.025 billion; and
- **Spectra Energy Corp** in its combination with Enbridge Inc. for \$28 billion.

Mr. Spinowitz has been repeatedly selected for inclusion in *Chambers USA* and *The Best Lawyers in America*. Prior to joining Skadden, he served as a law clerk to Judge Michael Boudin on the U.S. Court of Appeals for the First Circuit, and Justice Antonin Scalia on the U.S. Supreme Court.

## Recent Publications

"USA" chapter, *The Inward Investment and International Taxation Review*, 2022

"Biden Administration's Green Book Proposes Significant Changes to Tax Regime," *Skadden, Arps, Meagher & Flom LLP*, June 28, 2021

"Is Tax Competition Dead?" *Skadden, Arps, Meagher & Flom LLP*, June 16, 2021

"Biden Administration's Green Book Proposes Significant Changes to Tax Regime," *Skadden, Arps, Meagher & Flom LLP*, June 15, 2021